Phigenix, Inc.
Records under this name other than the patents Phigenix, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 1 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,735,365 | Targeting PAX2 for the Induction of DEFB1-MEDIATED Tumor Immunity and Cancer Therapy now held by Musc Foundation for Research Development In force · Low confidence | In force | Low confidence | |
| US 8,623,617 | Detecting PAX2 for the Diagnosis of Breast Cancer now held by Musc Foundation for Research Development In force (reinstated) · Low confidence | In force (reinstated) | Low confidence | |
| US 8,722,367 | Detecting PAX2 for the Diagnosis of Breast Cancer now held by Musc Foundation for Research Development In force · Low confidence | In force | Low confidence | |
| US 8,080,534 | Targeting PAX2 for the Treatment of Breast Cancer Term ended Term ended Oct 16, 2026 · High confidence | Term ended | Term ended Oct 16, 2026 | High confidence |
| US 8,394,780 | Targeting PAX2 for the Treatment of Breast Cancer now held by Musc Foundation for Research Development Term ended Term ended Oct 16, 2026 · High confidence | Term ended | Term ended Oct 16, 2026 | High confidence |
| US 8,653,021 | Targeting PAX2 for the Treatment of Breast Cancer now held by Musc Foundation for Research Development Term ended Term ended Oct 16, 2026 · High confidence | Term ended | Term ended Oct 16, 2026 | High confidence |
| US 8,722,643 | Targeting EN2, PAX2, And/Or DEFB1 for Treatment of Prostate Conditions now held by Musc Foundation for Research Development Term ended Term ended Oct 16, 2026 · High confidence | Term ended | Term ended Oct 16, 2026 | High confidence |
| US 11,033,628 | Targeting PAX2 for the Treatment of Breast Cancer Term ended Term ended Oct 16, 2026 · High confidence | Term ended | Term ended Oct 16, 2026 | High confidence |
| US 12,064,403 | Targeting PAX2 for the Treatment of Breast Cancer Term ended Term ended Oct 16, 2026 · High confidence | Term ended | Term ended Oct 16, 2026 | High confidence |
| US 8,633,149 | Targeting PAX2 for the Treatment of Breast Cancer now held by Musc Foundation for Research Development Lapsed on the fee record Ended Jan 21, 2026 · High confidence | Lapsed on the fee record | Ended Jan 21, 2026 | High confidence |